Literature DB >> 22074132

Locating the source of hyperglycemia: liver versus muscle.

Haoyong Yu1, Dequan Zhou, Weiping Jia, ZengKui Guo.   

Abstract

BACKGROUND: Glucose homeostasis relies on insulin to suppress hepatic glucose production and to stimulate glucose uptake by peripheral tissues (primarily skeletal muscle) during and after a meal or glucose load. Glucose metabolism impairments in the liver and/or muscle attenuate these insulin actions, causing hyperglycemia. Thus, identifying the loci of the impairments can improve the understanding of hyperglycemia and enable organ-targeted interventions.
METHODS: Studies were performed to identify such loci using modified oral glucose tolerance test (OGTT) techniques in individuals with type 2 diabetes (T2D) and overweight/obese individuals.
RESULTS: Individuals with severe T2D were found to have significantly impaired glucose metabolism in both the liver and muscle. In contrast, impairments in glucose metabolism in individuals with non-severe T2D were predominantly localized in the liver or muscle, but not both. Similarly, milder impairments in overweight or obese individuals were clearly localized in either the liver or muscle, but not both. All these impairments are quantifiable.
CONCLUSION: Impairments in glucose metabolism in the liver and muscle can be differentiated and quantified in a clinical setting.
© 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22074132      PMCID: PMC4234049          DOI: 10.1111/j.1753-0407.2011.00170.x

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  18 in total

1.  The oral glucose tolerance test (OGTT): effect of rate of ingestion of carbohydrate and different carbohydrate preparations.

Authors:  R J Heine; I Hanning; L Morgan; K G Alberti
Journal:  Diabetes Care       Date:  1983 Sep-Oct       Impact factor: 19.112

2.  Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.

Authors:  N Wollen; C J Bailey
Journal:  Biochem Pharmacol       Date:  1988-11-15       Impact factor: 5.858

3.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Authors:  S E Inzucchi; D G Maggs; G R Spollett; S L Page; F S Rife; V Walton; G I Shulman
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver.

Authors:  J Radziuk; Z Zhang; N Wiernsperger; S Pye
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

5.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Authors:  Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

6.  Pioglitazone has direct effects on insulin sensitivity and intracellular lipid content in L6 skeletal muscle cells.

Authors:  M Kranebitter; A Niederwanger; T Tatarczyk; C Ciardi; R Al-Zoairy; J R Patsch; M T Pedrini
Journal:  Horm Metab Res       Date:  2010-10-13       Impact factor: 2.936

7.  Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes.

Authors:  R C Bonadonna; S Del Prato; M P Saccomani; E Bonora; G Gulli; E Ferrannini; D Bier; C Cobelli; R A DeFronzo
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes.

Authors:  B Yu; S Pugazhenthi; R L Khandelwal
Journal:  Biochem Pharmacol       Date:  1994-08-30       Impact factor: 5.858

9.  Role of hepatic glucose production and glucose uptake in the pathogenesis of fasting hyperglycemia in type 2 diabetes: normalization of glucose kinetics by short-term fasting.

Authors:  F Féry
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

Review 10.  Control of glycaemia.

Authors:  J E Gerich
Journal:  Baillieres Clin Endocrinol Metab       Date:  1993-07
View more
  3 in total

1.  Metabolic profiling of tissue-specific insulin resistance in human obesity: results from the Diogenes study and the Maastricht Study.

Authors:  Ellen E Blaak; Ilja C W Arts; Nicole Vogelzangs; Carla J H van der Kallen; Marleen M J van Greevenbroek; Birgitta W van der Kolk; Johan W E Jocken; Gijs H Goossens; Nicolaas C Schaper; Ronald M A Henry; Simone J P M Eussen; Armand Valsesia; Thomas Hankemeier; Arne Astrup; Wim H M Saris; Coen D A Stehouwer
Journal:  Int J Obes (Lond)       Date:  2020-03-17       Impact factor: 5.095

2.  Reducing Liver Fat by Low Carbohydrate Caloric Restriction Targets Hepatic Glucose Production in Non-Diabetic Obese Adults with Non-Alcoholic Fatty Liver Disease.

Authors:  Haoyong Yu; Weiping Jia; ZengKui Guo
Journal:  J Clin Med       Date:  2014-09       Impact factor: 4.241

Review 3.  Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity.

Authors:  Kelsey H Collins; Walter Herzog; Graham Z MacDonald; Raylene A Reimer; Jaqueline L Rios; Ian C Smith; Ronald F Zernicke; David A Hart
Journal:  Front Physiol       Date:  2018-02-23       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.